A new study reveals many inhibitory neurons are lost in early phases of ALS and FTD development. The findings show a contrast to other neurodegenerative diseases where excitatory neurons are lost early in the disorders.
New findings could help develop treatments to slow the progression of ALS.
A novel method detected conformational changes to the TDP-43 protein in cerebral spinal fluid associated with ALS.
New studies find a drug designed to combat the gene that causes SCA2 could also be beneficial in the fight against ALS.
Researchers report they have identified a molecular defect in motor neurons which could help explain the mechanisms underlying ALS.
Researchers have developed a new model to study neurodegenerative diseases which affect motor neurons, such as ALS.
A new mouse model has been developed that captures the pathology of sporadic neurodegenerative diseases.
Researchers have identified two proteins that prevent the formation of scars in the brain and help promote the regeneration of new neural tissue.
Performing post-mortem staging of the brains and spinal cord tissue of patients with ALS, researchers discover the neurodegenerative disease could progress from one start point in the CNS to other regions of the brain and spinal cord.
c9ASO, an investigational ASO drug, targets the TDP-43 protein, reducing its buildup and decreasing neurological decline associated with ALS and FTD.
Researchers have developed a new mouse model of ALS that could help provide better understanding of the progressive nature of the disease.
Researchers discover a new way of reducing disease toxicity in ALS which slows the dysfunction of neurons.
